Ard Jamy D, Gower Barbara, Hunter Gary, Ritchie Christine S, Roth David L, Goss Amy, Wingo Brooks C, Bodner Eric V, Brown Cynthia J, Bryan David, Buys David R, Haas Marilyn C, Keita Akilah Dulin, Flagg Lee Anne, Williams Courtney P, Locher Julie L
Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Department of Nutrition Sciences, University of Alabama at Birmingham.
J Gerontol A Biol Sci Med Sci. 2017 Dec 12;73(1):73-80. doi: 10.1093/gerona/glw237.
We lack a comprehensive assessment of the risks and benefits of calorie restriction in older adults at high risk for cardiometabolic disease. Calorie restriction may reduce visceral adipose tissue (VAT) but also have negative effects on lean mass and quality of life.
We conducted a 52-week, randomized controlled trial involving 164 older adults with obesity taking at least one medication for hyperlipidemia, hypertension, or diabetes. Interventions included an exercise intervention alone (Exercise), or with diet modification and body weight maintenance (Maintenance), or with diet modification and energy restriction (Weight Loss). The primary outcome was change in VAT at 12 months. Secondary outcomes included cardiometabolic risk factors, functional status, and quality of life.
A total of 148 participants had measured weight at 12 months. Despite loss of -1.6% ± 0.3% body fat and 4.1% ± 0.7% initial body weight, Weight Loss did not have statistically greater loss of VAT (-192.6 ± 185.2 cm3) or lean mass (-0.4 ± 0.3 kg) compared with Exercise (VAT = -21.9 ± 173.7 cm3; lean mass = 0.3 ± 0.3 kg). Quality of life improved in all groups with no differences between groups. No significant changes in physical function were observed. Weight Loss had significantly greater improvements in blood glucose (-8.3 ± 3.6 mg/dL, p < .05) and HDL-cholesterol (5.3 ± 1.9, p < .01) compared with Exercise. There were no group differences in the frequency of adverse events.
While moderate calorie restriction did not significantly decrease VAT in older adults at high risk for cardiometabolic disease, it did reduce total body fat and cardiometabolic risk factors without significantly more adverse events and lean mass loss.
我们缺乏对心血管代谢疾病高风险老年人热量限制的风险和益处的全面评估。热量限制可能会减少内脏脂肪组织(VAT),但也会对瘦体重和生活质量产生负面影响。
我们进行了一项为期52周的随机对照试验,纳入了164名肥胖的老年人,他们至少服用一种治疗高脂血症、高血压或糖尿病的药物。干预措施包括单独的运动干预(运动组),或运动加饮食调整和体重维持(维持组),或运动加饮食调整和能量限制(减重组)。主要结局是12个月时VAT的变化。次要结局包括心血管代谢危险因素、功能状态和生活质量。
共有148名参与者在12个月时测量了体重。尽管减重组的体脂减少了-1.6%±0.3%,初始体重减轻了4.1%±0.7%,但与运动组相比,减重组的VAT减少量(-192.6±185.2 cm³)或瘦体重减少量(-0.4±0.3 kg)在统计学上并没有显著更大(运动组VAT=-21.9±173.7 cm³;瘦体重=0.3±0.3 kg)。所有组的生活质量均有所改善,组间无差异。未观察到身体功能有显著变化。与运动组相比,减重组的血糖(-8.3±3.6 mg/dL,p<.05)和高密度脂蛋白胆固醇(5.3±1.9,p<.01)有显著更大的改善。不良事件发生频率在组间无差异。
虽然适度的热量限制并未显著降低心血管代谢疾病高风险老年人的VAT,但它确实减少了全身脂肪和心血管代谢危险因素,且不良事件和瘦体重损失并未显著增加。